Board of Pharmacy advances new compounding regulations after marathon public comments; 15-day posting approved

Sacramento — The California State Board of Pharmacy voted March 6 to publish a fourth modified text of proposed changes to Title 16 of the California Code of Regulations covering sterile and nonsterile compounding, hazardous drugs and radiopharmaceuticals and to open a 15-day public comment period on that text.

The board’s Enforcement Committee members presented a summary of comments received and staff recommendations before the vote. Board member Maria Serpa, chair of the Enforcement Committee, told colleagues, “As the record shows, we received far fewer comments during this 15 day public comment period.” The package before the board included proposed deletions and additions to several section numbers and a third-modified text that staff recommended further revise.

Why it matters: The rule package aims to clarify local regulatory expectations where federal guidance and United States Pharmacopeia (USP) standards intersect, while also spelling out requirements for immediate-use situations, the handling of certain bulk drug substances, and standard operating procedures (SOPs) for compounding facilities. Stakeholders and patients said the outcome will affect access to often niche compounded therapies, while compounding and hospital pharmacy groups cautioned against duplicative or overly prescriptive state standards that go beyond USP and federal guidance.

What the board approved: The motion — offered by board member Maria Serpa and seconded by Renee Barker — accepted staff responses to comments on the third modified text, approved the recommended fourth modified text (dated 02/28/2025) for a 15-day public comment period, and delegated to Serpa and Barker (with authority for the executive officer to make non‑substantive edits) the ability to review any additional comments arising during that period and recommend further changes to the board.

Board discussion and staff framing: Committee and staff presentations emphasized that the rulemaking has been in development since 2019 and that the proposed changes are intended to align state regulation with USP standards while filling gaps commenters said caused confusion. The recommended revisions addressed three main areas identified in the March 6 materials: clarification on immediate-use provisions (what triggers required reporting and what is allowed when sterile environments fail), handling of sterile compounding using bulk drug substances listed on the FDA interim list (including requirements for certificates of analysis and SOPs establishing component-acceptance processes), and glove-use language consistent with USP.

Public testimony: The board heard more than two hours of public comment from clinicians, pharmacists, patient advocates and dozens of people identifying as firefighters or patients who said they rely on compounded sterile nutrients such as glutathione and methylcobalamin. Commenters voiced two recurring themes: calls to align state rules with USP and federal guidance, and concerns that new state requirements would limit access to compounded treatments.

Representative public comments included: Marie Cotman, who told the board the rules are “excessive” and “still confusing” and warned they could reduce the number of compounding pharmacies; a number of firefighters and family members who described respiratory symptoms after recent fires and urged access to nebulized or IV glutathione; and pharmacists and health systems (including a Kaiser Permanente speaker) who said the USP compounding chapters provide evidence-based standards the state should not exceed without empirical justification.

Enforcement and professional judgment: Board counsel and staff clarified that USP standards and an FDA interim enforcement policy are part of the regulatory context and that the board’s approach balances prescriptive requirements with areas where professional judgment will apply. Counsel reminded members that oversight limits exist—healing-arts boards retain jurisdiction over their licensees—and explained the board’s hybrid enforcement model, where inspection findings are reviewed by pharmacy-trained staff and enforcement decisions consider facts, prior history and mitigation.

Vote: The motion carried. (See the article’s actions[] entry for the motion text, movers, and the recorded roll-call votes.)

Votes at a glance (other regulatory actions taken March 6): - Discontinuance-of-business amendment to Title 16, section 1708.2: board approved staff recommended modifications and authorized a second 15-day comment period; the executive officer was delegated authority to complete rulemaking if no adverse comments are received. - Quality-assurance (QA) regulation, Title 16, section 1711: the board deferred final action and directed staff to work with two members (board members Jay and Maria Serpa) to return with proposed language emphasizing system-level review and minimum expectations for QA programs. - Digital-signature regulation, new section 1700: the board adopted the proposed text consistent with Government Code section 16.5 and authorized staff to complete rulemaking.

What’s next: The board delegated authority to members and staff for post-comment review and sign‑off on technical edits for the compounding text; the board also set a follow-up full meeting for March 26, 2025, to continue rulemaking work. The fourth modified text will be posted for 15 days; staff will return to the board with recommendations based on any new comments that period produces.

Ending: The board’s action continues a multi-year rulemaking effort meant to specify how California pharmacies must handle complex sterile compounding tasks. Opponents and supporters told the board they will use the additional 15-day comment window to press for clearer language tied to access, patient safety and enforceability.